Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases Under Immunomodulators
Efficacy, Immunogenicity, and Safety of the Recombinant Herpes Zoster Vaccine (RZV) in Patients With Autoimmune Rheumatic Diseases Under Immunomodulators
University of Sao Paulo General Hospital
200 participants
Dec 2, 2025
INTERVENTIONAL
Conditions
Summary
This interventional phase IV clinical trial will evaluate the efficacy, immunogenicity and safety of the adjuvanted recombinant herpes zoster vaccine (RZV) in adults with autoimmune rheumatic diseases (ARDs) receiving immunomodulatory monotherapy. Humoral immune response will be quantified by anti-glycoprotein E (anti-gE) antibody titers. Patients will receive two doses of RZV. Outcomes include seroconversion and geometric mean titers six weeks after completion of the vaccination schedule, persistence of antibody titers at one year, and incidence of confirmed herpes zoster during follow-up.
Eligibility
Inclusion Criteria7
- Adults aged 18 years or older.
- Diagnosis of an autoimmune rheumatic disease (such as rheumatoid arthritis, systemic lupus erythematosus, axial spondyloarthritis, psoriatic arthritis, systemic sclerosis, Sjögren syndrome, idiopathic inflammatory myopathies, or primary systemic vasculitis) according to validated classification criteria.
- Clinical stability at the time of enrollment, defined as no change in disease-modifying therapy or corticosteroid dose in the preceding four weeks and no evidence of infection or disease flare.
- Current use of hydroxychloroquine or sulfasalazine in monotherapy for at least three months prior to inclusion.
- Can be under prednisone use of 5mg/week.
- Ability and willingness to comply with study procedures and follow-up visits.
- Provision of written informed consent.
Exclusion Criteria9
- Previous vaccination with recombinant zoster vaccine (RZV).
- History of herpes zoster or varicella infection within 12 months before enrollment.
- Concomitant use of systemic immunosuppressive therapy including but not limited to methotrexate, mycophenolate mofetil, azathioprine, cyclophosphamide, biologics, or JAK inhibitors.
- Use of glucocorticoids >5mg/week.
- Acute febrile illness or active infection at the time of vaccination.
- Pregnancy or breastfeeding.
- Known hypersensitivity to any component of the recombinant zoster vaccine.
- History of Guillain-Barré syndrome.
- Any condition that, in the investigators' judgment, could interfere with study participation or interpretation of results.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
VRZ (Shingrix®) is composed of 50 μg of recombinant VZV glycoprotein E (gE) and the liposome-based AS01B (HZ/su) adjuvant system (containing 50 μg of 3-O-desacyl-4'-monophosphoryl lipid A \[MPL\] and 50 μg of Quillaja saponaria Molina, fraction 21 (QS21), licensed by GSK from Antigenics, a subsidiary of Agenus). Two doses of the vaccine will be administered (0.5 mL) into the deltoid muscle on days (D) 0 and D42.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07280741